Fighting Childhood Pneumonia in Uganda: A Policy Solution
This paper examines the persistent challenge of childhood pneumonia mortality among children under five in Uganda, drawing on Calkins and Palamountain's case study. It reviews past intervention efforts — including Village Health Teams, the Sustainable Drug Seller Initiative, and Pharmaceutical Manufacturer Negotiations — and explains why each fell short due to cost, donor fatigue, or inadequate government oversight. The paper then proposes a two-pronged solution: establishing a domestic pharmaceutical manufacturing plant to produce pneumonia drugs, thereby reducing foreign dependence and recurring costs, and implementing a selective drug-shop accreditation and training program to extend first-line diagnostic care. Together, these approaches aim to create a self-sustaining healthcare infrastructure with potential applicability across other developing nations.
- Introduction: Childhood pneumonia mortality crisis in Uganda
- Past Approaches and Their Limitations: Why prior interventions failed to reduce deaths
- Proposed Solution: Local Drug Manufacturing: Building domestic pharmaceutical capacity in Uganda
- Accredited Drug-Shop Training Program: Training shopkeepers as first-line healthcare providers
- Combining Both Approaches and Broader Implications: Merging solutions for sustainable, scalable impact
- Conclusion: Uganda as model for other developing nations
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its policy argument in concrete case-study evidence, citing specific statistics (20,000 child deaths in 2012, 15% of under-five mortality) to establish urgency before proposing solutions.
- It systematically diagnoses why prior interventions failed — particularly the recurring-cost and donor-fatigue problems — and uses those diagnoses to directly motivate the proposed dual solution, creating a tight logical chain.
- The paper draws on multiple authoritative sources (WHO data, UN Human Rights Council, World Bank publication) to reinforce its recommendation for local pharmaceutical production, lending the argument international credibility.
Key academic technique demonstrated
The paper demonstrates problem-solution structuring: it first maps the failure conditions of existing interventions, then derives solution criteria directly from those failures (self-sustainability, minimal ongoing supervision, one-off capital outlay). Each element of the proposed solution is explicitly tied back to a diagnosed weakness, showing strong analytical coherence between the problem and the remedy.
Structure breakdown
The paper opens with an introduction establishing the scope and urgency of childhood pneumonia in Uganda. A discussion section surveys prior interventions and identifies their shared weaknesses. The proposed solution section introduces local pharmaceutical manufacturing and then drug-shop training as complementary measures. A synthesis paragraph explains how the two approaches reinforce each other and notes Uganda's "pathfinder" status as justification for broader replication. References follow in APA format.
Introduction
As Calkins and Palamountain (2017) point out in their article "Fighting Childhood Pneumonia in Uganda," pneumonia remains one of the leading causes of death for children under the age of five around the world. More children have died from pneumonia-related complications in recent times than from measles, malaria, and HIV combined. This is a clear indication of the severity of the issue — particularly in developing countries. In Uganda, for instance, "approximately 20,000 children under five died from the illness" in 2012, a figure representing "15 percent of under-five deaths in Uganda" (Calkins and Palamountain, 2017, p. 10). Various initiatives have been undertaken by both the government and international non-governmental organizations (INGOs) in an attempt to address the situation; however, no single approach has yielded significant benefits.
Taking the context of this discussion into consideration, the all-important question remains: what would be the most effective approach towards reducing childhood mortality rates in this case? The key consideration on this front would be to make an impact with limited INGO funding over a specified period of time.
Past Approaches and Their Limitations
Many approaches have been adopted in an attempt to battle childhood pneumonia in Uganda. Despite these efforts, childhood pneumonia remains a serious challenge. According to Calkins and Palamountain, some of the approaches implemented in the past include Village Health Teams, the Sustainable Drug Seller Initiative, Patient Awareness Campaigns, Pharmaceutical Manufacturer Negotiations, and Healthcare Provider Training and Diagnostics. The failure to significantly reduce child mortality rates despite these interventions indicates that the problem is particularly complex.
One of the key issues limiting the success of these initiatives is cost. Village Health Teams (VHTs), for instance, could have proven too costly if rolled out across the country — especially given that finding volunteers proved to be a challenge. It is also important to note that overreliance on INGOs to fund initiatives with recurring expenditure over the long term is a gamble, as donors can experience donor fatigue; their eventual exit would be fatal and could effectively erode any gains made.
The government of Uganda cannot be relied upon as an effective long-term partner in supervising ongoing programs, particularly where cost is a concern. This was evident in the Sustainable Drug Seller Initiative, which attempted to address childhood pneumonia by enhancing drug-shop sellers' training and diagnostic skills for respiratory illness. In that case, "monitoring by the government was too infrequent to be meaningful" (Calkins and Palamountain, 2017, p. 13). The most workable approach should therefore be self-sustaining and require minimal — if any — ongoing supervision or monitoring.
Proposed Solution: Local Drug Manufacturing
Given the key issues identified, the approach with the most potential impact would involve combining infrastructural investment with training. Donor funds could be allocated toward establishing a drug manufacturing plant in Uganda, developed in partnership with the government and a reputable pharmaceutical company. The plant would focus on producing drugs to combat pneumonia. Experts cited by Calkins and Palamountain have already expressed the view that this approach could help eliminate the persistent challenge of childhood pneumonia mortality.
One of the primary advantages of this approach is that it requires a one-off capital outlay with no significant recurring expenditure after completion. This effectively eliminates the concern of donor fatigue and its associated risks. In addition to building local expertise, the country could benefit from increased employment opportunities for its citizens while reducing or eliminating dependence on foreign drug suppliers.
This approach has gained traction in international circles. The Director of the Division on Investment and Enterprise at the United Nations Conference on Trade and Development has noted that local production of medicines could be highly relevant "for developing countries to ensure the security of access to medicines for their populations," and that such countries should be assisted "to build their competitive edge in the production of generic medicine" (United Nations Human Rights, 2017). The World Health Organization further points out that approximately "30 percent of the world's population — approximately 2 billion people — still lacks regular access to essential medicines" (Nkrumah and Mensah, 2014, p. 111), with the situation being considerably worse in developing countries. Local pharmaceutical production would improve access to antibiotics in Uganda, with cost savings arising from factors including, but not limited to, reduced transportation costs.
Conclusion
Upon the successful implementation of the approach highlighted herein, the same framework could be adopted in other developing nations to address other challenging health concerns such as malaria and HIV/AIDS. This is especially pertinent given that Uganda, as Calkins and Palamountain point out, holds pathfinder country status — meaning it "could serve as an example for other countries wrestling with the same issues."
References
Calkins, T., & Palamountain, K. (2017). Fighting childhood pneumonia in Uganda. Retrieved from
Nkrumah, Y., & Mensah, J. (Eds.). (2014). Accelerating health reforms through collective action: Experiences from East Africa. Washington, DC: World Bank Publications.
United Nations Human Rights. (2017). Human Rights Council holds panel discussion on access to medicines. Retrieved from http://www.ohchr.org/EN/NewsEvents/Pages/DisplayNews.aspx?NewsID=21325&LangID=E
Create your account
Always verify citation format against your institution’s current style guide requirements.